LT4161927T - Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas - Google Patents

Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas

Info

Publication number: LT4161927T
Authority: LT; Lithuania
Prior art keywords: melanocortin; receptor antagonists; spiro compounds; spiro; compounds
Prior art date: 2020-06-09

Application number

LTEPPCT/IB2021/054970T

Other languages

English (en)

Inventor

Christopher Ryan BUTLER

Michelle Renee GARNSEY

Kevin Alexander OGILVIE

Jana Polivkova

Matthew Forrest Sammons

Aaron Christopher Smith

Qingyi YANG

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-06-09

Filing date

2021-06-07

Publication date

2024-09-25

2021-06-07 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2024-09-25 Publication of LT4161927T publication Critical patent/LT4161927T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

LTEPPCT/IB2021/054970T 2020-06-09 2021-06-07 Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas LT4161927T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US202063036798P	2020-06-09	2020-06-09
US202163167271P	2021-03-29	2021-03-29
PCT/IB2021/054970 WO2021250541A1 (en)	2020-06-09	2021-06-07	Spiro compounds as melanocortin 4 receptor antagonists and uses thereof

Publications (1)

Publication Number	Publication Date
LT4161927T true LT4161927T (lt)	2024-09-25

Family

ID=76422026

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/IB2021/054970T LT4161927T (lt)	2020-06-09	2021-06-07	Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas

Country Status (33)

Country	Link
US (3)	US11643412B2 (lt)
EP (1)	EP4161927B9 (lt)
JP (1)	JP7288554B1 (lt)
KR (1)	KR102838870B1 (lt)
CN (1)	CN116113635B (lt)
AU (1)	AU2021289169B2 (lt)
BR (1)	BR112022024527A2 (lt)
CA (1)	CA3186348A1 (lt)
CL (1)	CL2022003503A1 (lt)
CO (1)	CO2022017790A2 (lt)
CR (1)	CR20220632A (lt)
DK (1)	DK4161927T3 (lt)
DO (1)	DOP2022000281A (lt)
EC (1)	ECSP22093794A (lt)
ES (1)	ES2994968T3 (lt)
FI (1)	FI4161927T3 (lt)
HR (1)	HRP20241177T1 (lt)
HU (1)	HUE068344T2 (lt)
IL (1)	IL298891A (lt)
LT (1)	LT4161927T (lt)
MA (1)	MA59895B1 (lt)
MD (1)	MD4161927T3 (lt)
MX (1)	MX2022015706A (lt)
PE (1)	PE20231215A1 (lt)
PH (1)	PH12022553296A1 (lt)
PL (1)	PL4161927T3 (lt)
PT (1)	PT4161927T (lt)
RS (1)	RS65929B9 (lt)
SI (1)	SI4161927T1 (lt)
TW (1)	TWI843949B (lt)
UY (1)	UY39260A (lt)
WO (1)	WO2021250541A1 (lt)
ZA (1)	ZA202213427B (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11704494B2 (en) *	2019-05-31	2023-07-18	Ab Initio Technology Llc	Discovering a semantic meaning of data fields from profile data of the data fields
JP7573009B2 (ja)	2021-12-06	2024-10-24	ファイザー・インク	メラノコルチン４受容体アンタゴニストとしてのスピロ化合物およびそれらの使用
AU2023379802A1 (en)	2022-11-17	2025-06-26	Changchun Genescience Pharmaceutical Co., Ltd.	Mc4r antagonist compound, pharmaceutical composition and pharmaceutical use thereof
AU2024221787A1 (en) *	2023-02-17	2025-09-04	Endevica Bio, Inc.	Methods of preventing and/or treating side effects associated with anti-cancer agents using non-naturally occurring melanocortin analogs with anti-gdf-15 antibodies
WO2024255412A1 (zh) *	2023-06-14	2024-12-19	广州必贝特医药股份有限公司	螺杂环化合物及其应用
WO2024260932A2 (en)	2023-06-19	2024-12-26	F. Hoffmann-La Roche Ag	Process for the preparation of a chiral pyrrolo triazole alcohol

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CA1146866A (en)	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de)	1984-10-23	1986-04-30	Rentschler Arzneimittel	Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
EP0580860B2 (en)	1991-04-16	2004-12-15	Nippon Shinyaku Company, Limited	Method of manufacturing solid dispersion
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja)	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de)	1995-02-14	1996-08-22	Basf Ag	Feste Wirkstoff-Zubereitungen
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt)	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CN1149196C (zh)	1998-07-06	2004-05-12	布里斯托尔-迈尔斯斯奎布公司	作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
WO2004081643A1 (en) *	2002-12-20	2004-09-23	Kaiser Aerospace & Electronics Corp.	Lenslet array with polarization conversion
EP1460073A1 (en) *	2003-03-20	2004-09-22	MyoContract Ltd.	Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
HRP20090471T1 (hr)	2004-05-12	2009-10-31	Pfizer Products Inc.	Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
BRPI0616463A2 (pt) *	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
BRPI0708264A2 (pt)	2006-02-23	2011-05-24	Pfizer Ltd	piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
WO2007114323A1 (ja) *	2006-04-04	2007-10-11	Taisho Pharmaceutical Co., Ltd.	アミノピロリジン化合物
EP2463283B1 (en)	2006-04-20	2014-06-11	Pfizer Products Inc.	Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
JP2011529483A (ja)	2008-07-29	2011-12-08	ファイザー・インク	フッ素化ヘテロアリール
MX2011002166A (es)	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
FR2937868B1 (fr)	2008-11-04	2010-11-05	Galderma Res & Dev	Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2210885A1 (en)	2009-01-14	2010-07-28	Santhera Pharmaceuticals (Schweiz) AG	Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) *	2009-02-27	2010-09-02	Mimetica Pty Ltd	Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
CA2754685A1 (en)	2009-03-11	2010-09-16	Pfizer Inc.	Substituted indazole amides
JP5086480B2 (ja)	2009-03-11	2012-11-28	ファイザー・インク	グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
US20120095028A1 (en)	2009-03-20	2012-04-19	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010128414A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
CA2759843A1 (en)	2009-05-08	2010-11-10	Pfizer Inc.	Gpr 119 modulators
NZ596467A (en)	2009-06-05	2014-01-31	Pfizer	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
US9637453B2 (en)	2015-04-17	2017-05-02	Forma Therapeutics, Inc.	3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
TR201618240A2 (tr)	2016-12-09	2017-01-23	Ahmet Elibol	Aort kapak koruyucu kök replasman ameli̇yatlarinda kullanilan ölçüm ve si̇mülasyon terti̇bati
MA56480B1 (fr)	2016-12-16	2022-12-30	Pfizer	Agonistes du récepteur glp-1 et leurs utilisations
BR112019014688A2 (pt) *	2017-01-20	2020-02-18	Pfizer Inc.	Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
NL2019545B1 (en)	2017-09-14	2019-03-27	Univ Delft Tech	Instrument for minimal invasive surgical operations, comprising a rod or catheter and a tip mounted on the rod or catheter with an elastically deformable element

2021
- 2021-06-07 LT LTEPPCT/IB2021/054970T patent/LT4161927T/lt unknown
- 2021-06-07 AU AU2021289169A patent/AU2021289169B2/en active Active
- 2021-06-07 CR CR20220632A patent/CR20220632A/es unknown
- 2021-06-07 CA CA3186348A patent/CA3186348A1/en active Pending
- 2021-06-07 SI SI202130198T patent/SI4161927T1/sl unknown
- 2021-06-07 EP EP21732126.4A patent/EP4161927B9/en active Active
- 2021-06-07 DK DK21732126.4T patent/DK4161927T3/da active
- 2021-06-07 MA MA59895A patent/MA59895B1/fr unknown
- 2021-06-07 MD MDE20230408T patent/MD4161927T3/ro unknown
- 2021-06-07 CN CN202180056466.1A patent/CN116113635B/zh active Active
- 2021-06-07 FI FIEP21732126.4T patent/FI4161927T3/fi active
- 2021-06-07 RS RS20240965A patent/RS65929B9/sr unknown
- 2021-06-07 MX MX2022015706A patent/MX2022015706A/es unknown
- 2021-06-07 KR KR1020227042755A patent/KR102838870B1/ko active Active
- 2021-06-07 HR HRP20241177TT patent/HRP20241177T1/hr unknown
- 2021-06-07 PE PE2022002902A patent/PE20231215A1/es unknown
- 2021-06-07 HU HUE21732126A patent/HUE068344T2/hu unknown
- 2021-06-07 BR BR112022024527A patent/BR112022024527A2/pt unknown
- 2021-06-07 WO PCT/IB2021/054970 patent/WO2021250541A1/en not_active Ceased
- 2021-06-07 IL IL298891A patent/IL298891A/en unknown
- 2021-06-07 ES ES21732126T patent/ES2994968T3/es active Active
- 2021-06-07 PL PL21732126.4T patent/PL4161927T3/pl unknown
- 2021-06-07 PT PT217321264T patent/PT4161927T/pt unknown
- 2021-06-07 JP JP2022575378A patent/JP7288554B1/ja active Active
- 2021-06-07 PH PH1/2022/553296A patent/PH12022553296A1/en unknown
- 2021-06-08 TW TW110120795A patent/TWI843949B/zh active
- 2021-06-08 UY UY0001039260A patent/UY39260A/es unknown
- 2021-06-08 US US17/341,877 patent/US11643412B2/en active Active
2022
- 2022-12-07 CO CONC2022/0017790A patent/CO2022017790A2/es unknown
- 2022-12-08 DO DO2022000281A patent/DOP2022000281A/es unknown
- 2022-12-09 EC ECSENADI202293794A patent/ECSP22093794A/es unknown
- 2022-12-09 CL CL2022003503A patent/CL2022003503A1/es unknown
- 2022-12-12 ZA ZA2022/13427A patent/ZA202213427B/en unknown
2023
- 2023-01-31 US US18/162,052 patent/US12187727B2/en active Active
2024
- 2024-11-21 US US18/954,736 patent/US20250084084A1/en active Pending

Also Published As

Publication number	Publication date
DK4161927T3 (da)	2024-08-26
MD4161927T2 (ro)	2024-11-30
TWI843949B (zh)	2024-06-01
PE20231215A1 (es)	2023-08-17
JP7288554B1 (ja)	2023-06-07
EP4161927B1 (en)	2024-08-07
FI4161927T3 (fi)	2024-10-03
IL298891A (en)	2023-02-01
AU2021289169B2 (en)	2024-01-04
RS65929B1 (sr)	2024-10-31
US20230019853A1 (en)	2023-01-19
ZA202213427B (en)	2023-07-26
RS65929B9 (sr)	2025-02-28
HRP20241177T1 (hr)	2024-11-22
CN116113635A (zh)	2023-05-12
US12187727B2 (en)	2025-01-07
MA59895B1 (fr)	2024-10-31
US20230174532A1 (en)	2023-06-08
KR20230011968A (ko)	2023-01-25
CN116113635B (zh)	2025-03-18
AU2021289169A1 (en)	2023-01-19
WO2021250541A1 (en)	2021-12-16
US20250084084A1 (en)	2025-03-13
UY39260A (es)	2022-01-31
MX2022015706A (es)	2023-01-24
CA3186348A1 (en)	2021-12-16
PL4161927T3 (pl)	2024-11-18
HUE068344T2 (hu)	2024-12-28
MD4161927T3 (ro)	2025-02-28
DOP2022000281A (es)	2023-01-15
SI4161927T1 (sl)	2024-11-29
CL2022003503A1 (es)	2023-09-01
TW202204357A (zh)	2022-02-01
CR20220632A (es)	2023-01-23
PH12022553296A1 (en)	2024-06-24
PT4161927T (pt)	2024-10-08
ECSP22093794A (es)	2023-01-31
EP4161927B9 (en)	2024-11-06
US11643412B2 (en)	2023-05-09
KR102838870B1 (ko)	2025-07-24
BR112022024527A2 (pt)	2022-12-27
ES2994968T3 (en)	2025-02-04
EP4161927A1 (en)	2023-04-12
JP2023525394A (ja)	2023-06-15
CO2022017790A2 (es)	2022-12-20

Publication	Publication Date	Title
ZA202213427B (en)	2023-07-26	Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
IL273924A (en)	2020-05-31	Muscarinic acetylcholine M4 receptor antagonists
SG11202012071TA (en)	2021-01-28	Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
EP4081525C0 (en)	2025-05-21	SPIROCYCLIC PIPERIDINE-BASED MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
IL185892A0 (en)	2008-02-09	Novel compounds and their isomers and pharmaceutical compositions containing the same as vanilloid receptor antagonists
IL292692A (en)	2022-07-01	mrgprx2 antagonists and their uses
IL274062A (en)	2020-06-30	Muscarinic acetylcholine M4 receptor antagonists
HUE071813T2 (hu)	2025-09-28	Gem-diszubsztituált piperidin melanokortin altípus-2 receptor (mc2r) antagonisták és felhasználásuk
IL195110A0 (en)	2009-09-22	Substituted spirocyclic cgrp receptor antagonists
IL271805A (en)	2020-02-27	M4 muscarinic acetylcholine receptor antagonists
IL276411A (en)	2020-09-30	M4 muscarinic acetylcholine receptor antagonists
CL2007002958A1 (es)	2008-05-09	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
ZA200808691B (en)	2010-03-31	Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
IL276949A (en)	2020-10-29	Anti-folate receptor 1 antibodies and their uses
IL277144A (en)	2020-10-29	Adenosine receptor antagonists and uses thereof
IL200310A0 (en)	2010-04-29	Fast dissociating dopamine 2 receptor antagonists
EP4037677A4 (en)	2023-05-03	ANTAGONISTS OF THE MUSCARIC ACETYLCHOLINE RECEPTOR M4
SI2091938T1 (sl)	2011-02-28	Piperidinilamino-piridazini in njihova uporaba kot hitro disociirajoči antagonisti dopamin 2 receptorja
SG11202104078PA (en)	2021-05-28	5-azaindazole derivatives as adenosine receptor antagonists
PL3625221T3 (pl)	2021-08-23	3-metylopirolidyno-2,5-dionowe pochodne użyteczne jako antagoniści receptora cgrp
GB202011604D0 (en)	2020-09-09	GLP-1 receptor antagonists
SG11202109857UA (en)	2021-10-28	Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia
HK40112174A (zh)	2025-01-17	毒蕈硷性乙酰胆硷受体m4的拮抗剂
HK40042161A (en)	2021-08-27	Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
GB202001620D0 (en)	2020-03-25	C-X-C motif chemokine receptor 4 antagonist